对硫胺复合物与金属的审查:它们作为抗癌药物的药理潜力
Przemysław Rozbicki1, Danuta Branowska1
1Institute of Chemical Sciences, Faculty of Science, University of Siedlce, 3 Maja 54 Street, PL-08-1103 Siedlce, Poland.
硫胺金属复合物显示出显著的抗癌潜力,往往与当前化疗药物相匹配或超过. 这篇评论强调了他们开发新型,不那么有毒的癌症治疗的希望.
科学领域:
- 协调化学 协调化学
- 药用化学 医学化学
- 在瘤学瘤学.
背景情况:
- 硫胺因其抗菌性质和新兴的抗癌潜力而闻名.
- 金属协调增强了硫胺的功效,选择性,并引入了新的抗癌机制.
- 缺乏一个系统的概述,将硫胺-金属复合物的特性与生物活性联系起来.
研究的目的:
- 系统地审查与过渡金属和主要金属组合的硫胺复合物.
- 专注于它们作为抗癌剂的药理潜力.
- 为了将生物特性与中心金属原子相关联.
主要方法:
- 关于硫胺金属复合物的文献综述 (2007-2025年).
- 对癌细胞系的代表性结构和细胞毒性数据的分析.
- 与参考药物 (如思) 和碳酸酶抑制研究的比较.
主要成果:
- 许多含有各种金属 (Ti, Cr, Mn, Re, Ru, Os, Ir, Pd, Pt, Cu, Ag, Au, Fe, Co, Ni, U, Ca, Mg, Bi) 的硫胺复合体具有抗癌活性.
- 许多复合物显示的细胞毒性与现有的化疗药物相当或超过.
- 与对照组相比,一些复合物对非癌细胞的毒性降低.
结论:
- 硫胺金属复合体是抗癌药物开发的一个有希望的领域.
- 这些复合物有可能提高疗效和减少副作用.
- 这些发现为未来的新型抗癌药物的合理设计策略提供了框架.
更多相关视频
07:20Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
相关概念视频
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Drug Metabolism: Phase II Reactions
Phase II Reactions: Miscellaneous Conjugation Reactions
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
